Drug intelligence / Profile preview

PF-07985819

Development stage: Phase 1
Lead developer: Pfizer
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PF-07985819 is an investigational prophylactic mRNA (modRNA) vaccine being developed by Pfizer for the prevention of pandemic influenza. It uses a modified RNA platform to encode influenza hemagglutinin antigens, enabling host cells to transiently express these viral proteins and elicit protective humoral and cellular immune responses. Designed for intramuscular administration, this quadrivalent-like modRNA flu vaccine aims to offer rapid, adaptable manufacturing and enhanced immunogenicity against emerging pandemic influenza strains compared with traditional inactivated or live-attenuated vaccines.

Other names: pandemic influenza modified RNA vaccine

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on PF-07985819.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07985819.

Explore the full profile